Molecular Partners (MOLN) Competitors $3.84 -0.05 (-1.16%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MOLN vs. BCYC, VECT, DNTH, MRVI, RLAY, KURA, AUTL, CGEM, SANA, and OPTShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Bicycle Therapeutics (BCYC), VectivBio (VECT), Dianthus Therapeutics (DNTH), Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), Kura Oncology (KURA), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), Sana Biotechnology (SANA), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Molecular Partners vs. Bicycle Therapeutics VectivBio Dianthus Therapeutics Maravai LifeSciences Relay Therapeutics Kura Oncology Autolus Therapeutics Cullinan Therapeutics Sana Biotechnology Opthea Bicycle Therapeutics (NASDAQ:BCYC) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Do analysts recommend BCYC or MOLN? Bicycle Therapeutics presently has a consensus price target of $25.00, suggesting a potential upside of 178.58%. Molecular Partners has a consensus price target of $12.00, suggesting a potential upside of 212.91%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts clearly believe Molecular Partners is more favorable than Bicycle Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70Molecular Partners 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community favor BCYC or MOLN? Bicycle Therapeutics received 133 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 70.53% of users gave Bicycle Therapeutics an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote. CompanyUnderperformOutperformBicycle TherapeuticsOutperform Votes14670.53% Underperform Votes6129.47% Molecular PartnersOutperform Votes1348.15% Underperform Votes1451.85% Which has better valuation and earnings, BCYC or MOLN? Molecular Partners has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$25.72M24.16-$180.66M-$3.14-2.86Molecular Partners$2.23M69.37-$69.04M-$1.92-2.00 Does the media refer more to BCYC or MOLN? In the previous week, Bicycle Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Bicycle Therapeutics and 5 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.65 beat Bicycle Therapeutics' score of 0.51 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in BCYC or MOLN? 86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, BCYC or MOLN? Bicycle Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Is BCYC or MOLN more profitable? Bicycle Therapeutics has a net margin of -450.64% compared to Molecular Partners' net margin of -1,043.01%. Bicycle Therapeutics' return on equity of -27.35% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-450.64% -27.35% -20.81% Molecular Partners -1,043.01%-39.31%-35.46% SummaryBicycle Therapeutics beats Molecular Partners on 11 of the 19 factors compared between the two stocks. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.84M$3.11B$5.58B$8.67BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-1.7833.8627.2320.12Price / Sales69.37477.03423.64161.29Price / CashN/A168.6838.2534.64Price / Book0.713.497.114.72Net Income-$69.04M-$72.35M$3.23B$247.80M7 Day Performance5.07%7.99%3.67%2.77%1 Month Performance-6.46%22.61%13.11%9.75%1 Year Performance-23.15%-16.11%32.12%15.01% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners2.4985 of 5 stars$3.84-1.2%$12.00+212.9%-6.8%$154.84M$2.23M-1.78180News CoverageGap UpBCYCBicycle Therapeutics3.3176 of 5 stars$8.30-2.9%$25.00+201.2%-62.7%$574.81M$25.72M-2.52240Analyst RevisionVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeDNTHDianthus Therapeutics1.383 of 5 stars$17.59+0.3%$53.00+201.3%-12.6%$565.69M$6.52M-7.0480Positive NewsAnalyst RevisionMRVIMaravai LifeSciences3.6695 of 5 stars$2.22+4.2%$6.64+199.0%-74.4%$565.35M$241.86M-1.35610Positive NewsRLAYRelay Therapeutics1.8975 of 5 stars$3.29+3.5%$17.67+437.0%-53.7%$564.05M$7.68M-1.26330KURAKura Oncology4.545 of 5 stars$6.42+1.9%$24.50+281.6%-67.4%$555.81M$67.99M-2.72130Positive NewsAnalyst RevisionAUTLAutolus Therapeutics2.6087 of 5 stars$2.07+8.4%$9.32+350.2%-42.5%$550.91M$9.01M-1.71330Positive NewsHigh Trading VolumeCGEMCullinan Therapeutics2.1388 of 5 stars$8.96+2.4%$32.00+257.1%-60.7%$528.77MN/A-3.1530SANASana Biotechnology2.3935 of 5 stars$2.34+6.4%$10.80+361.5%-57.9%$527.62MN/A-1.67380Positive NewsOPTOpthea0.6886 of 5 stars$3.41+7.2%$1.33-60.9%N/A$524.84M$87,666.000.008Gap Up Related Companies and Tools Related Companies Bicycle Therapeutics Competitors VectivBio Competitors Dianthus Therapeutics Competitors Maravai LifeSciences Competitors Relay Therapeutics Competitors Kura Oncology Competitors Autolus Therapeutics Competitors Cullinan Therapeutics Competitors Sana Biotechnology Competitors Opthea Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOLN) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MOLN Stock Free MOLN Stock Alerts